Definium Posts $51.0M Q3 Loss; $1.05B Cash Funds Operations Into 2030
DFTX has more than doubled off its 52-week low of $10.465.
Summary
Definium reported a $51.0 million Q3 net loss and roughly $1.05 billion in cash, enough to fund operations into 2030. The DT120 ODT NDA filing remains on track for the first half of 2027, and early positive DT402 autism data were reported.
Key Events · Earnings and Guidance · DFTX
-
Q3 Loss Narrows on Warrant Gain
Net loss was $51.0 million versus $67.3 million a year earlier, helped by a $12.35 million non-cash gain on remeasuring the 2022 USD financing warrants and $10.1 million of interest income.
-
Cash of $1.05 Billion Into 2030
Cash, equivalents and investments totaled approximately $1.05 billion at September 30, 2026, up from $411.6 million at December 31, 2025, and management says it funds operations into 2030.
-
DT120 NDA Filing Set for 1H 2027
With positive Phase 3 Voyage and Panorama topline results in GAD and Breakthrough Therapy designation in MDD, the DT120 ODT NDA filing remains on track for the first half of 2027; Phase 3 Ascend topline is expected in 2027.
-
DT402 Shows Early Autism Signal
A five-patient, open-label Phase 2a of DT402 in adults with autism spectrum disorder showed improvements across socialization and communication measures; the study was exploratory and not powered for statistical conclusions, with a multi-dosing study planned for 2027.
Analysis · DFTX · Life Sciences
For a late-stage biotech, the quarter itself is unremarkable: R&D rose to $46.1 million from $31.0 million and G&A to $26.1 million from $14.7 million as Definium staffs up for a commercial launch. The balance sheet is what matters. Roughly $1.05 billion in cash and investments, up from $411.6 million at year-end 2025, removes any financing overhang ahead of the DT120 ODT NDA filing targeted for the first half of 2027, and management says it funds operations into 2030. Flattering the reported net loss of $51.0 million was a $12.35 million non-cash gain on remeasuring the 2022 USD financing warrants — a mark-to-market entry tied to the share price, not cash and not new dilution. New to the story is DT402: positive initial Phase 2a results in five adults with autism spectrum disorder, an exploratory open-label study not powered for statistical conclusions, with a multi-dosing study planned for 2027.
How filings like this one have moved
In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DFTX was trading at $36.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.8B. The 52-week trading range was $10.46 to $49.70. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.